Strong Organic Sales Growth
Novonesis delivered organic sales growth of 8% in the first 9 months of 2025, with the third quarter growing by 6%. Growth was broad-based and mainly volume-driven.
Emerging Markets Performance
Emerging markets experienced a 12% growth, driven by increased local presence and tailored solutions, significantly outgrowing developed markets.
Adjusted EBITDA Margin Improvement
The adjusted EBITDA margin for the first 9 months was 37.3%, an increase of 1.3 percentage points compared to last year, despite significant currency headwinds.
Innovative Product Launches
Novonesis launched 19 new Biosolutions in 2025, including high-performance solutions for various industries, contributing significantly to growth.
Cash Flow and Earnings Growth
Free cash flow before acquisitions increased by 16% to EUR 668 million, and diluted adjusted earnings per share increased by 20%.